FAQ: Quantum BioPharma's BUY Rating and $45 Price Target from Kingswood Capital Partners

What is the main news about Quantum BioPharma?

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) received a BUY rating and a US$45 price target from Kingswood Capital Partners, based on discounted cash flow valuation assuming successful Phase 2 and 3 trials of lead candidate Lucid-MS between 2026-2028 and commercial launch in 2029.

Why is this analyst coverage significant for investors?

This coverage is significant because it provides an independent, unpaid valuation from Kingswood Capital Partners, led by Senior Equity Analyst Karen Sterling, PhD, CFA, offering professional analysis of Quantum BioPharma’s potential based on clinical trial success and future commercial prospects.

What is Quantum BioPharma’s lead drug candidate and what does it treat?

Quantum BioPharma’s lead compound is Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation (the underlying mechanism of multiple sclerosis) in preclinical models, developed through its wholly owned subsidiary Lucid Psycheceuticals Inc.

What other business segments does Quantum BioPharma operate?

Beyond drug development, Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership and royalty payments, plus maintains strategic investments through subsidiary FSD Strategic Investments Inc. representing property-secured loans.

How does the unbuzzd(TM) royalty agreement work?

Quantum BioPharma receives 7% royalty payments from unbuzzd(TM) sales until payments total $250 million, after which the royalty drops to 3% in perpetuity, while retaining 100% rights to develop similar products for pharmaceutical and medical uses.

Where can investors find more information about Quantum BioPharma?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/ and the full press release can be viewed at https://ibn.fm/S27oE.

What is the timeline for Lucid-MS development and commercialization?

The valuation assumes successful Phase 2 and 3 trials of Lucid-MS between 2026 and 2028, with a commercial launch projected for 2029, based on the discounted cash flow analysis by Kingswood Capital Partners.

What conditions does Quantum BioPharma focus on treating?

Quantum BioPharma develops treatments for neurodegenerative disorders, metabolic disorders, and alcohol misuse disorders, with drug candidates in different stages of development targeting these challenging conditions.